Array-based profiling of the differential methylation status of CpG islands in hepatocellular carcinoma cell lines

Liu,Bin-Bin; Zheng,Dan; Liu,Yin-Kun; Kang,Xiao-Nan; Sun,Lu; Guo,Kun; Sun,Rui-Xia; Chen,Jie; Zhao,Yan

doi:10.3892/ol_00000143

Array-based profiling of the differential methylation status of CpG islands in hepatocellular carcinoma cell lines

Authors:
- Bin-Bin Liu
- Dan Zheng
- Yin-Kun Liu
- Xiao-Nan Kang
- Lu Sun
- Kun Guo
- Rui-Xia Sun
- Jie Chen
- Yan Zhao
View Affiliations

Affiliations: Liver Cancer Institute, Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
Published online on: September 1, 2010 https://doi.org/10.3892/ol_00000143
Pages: 815-820

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alterations in the DNA methylation status particularly in CpG islands are involved in the initiation and progression of many types of human cancer. A number of DNA methylation alterations have been reported in hepatocellular carcinoma (HCC). However, a systematic analysis is required to elucidate the relationship between differential DNA methylation status and the characteristics and progression of HCC. In the present study, a global analysis of DNA methylation using a human CpG-island 12K array was performed on a number of HCC cell lines of different origin and metastatic potential. Based on a standard methylation alteration ratio of ≥2 or ≤0.5, 58 CpG island sites and 66 tumor-related genes upstream, downstream or within were identified. This study showed a series of CpG island methylation alterations in the HCC cell lines. The expression of various oncogenes, tumor suppressor genes and other key genes were up- or downregulated, respectively, resulting in CpG island hypomethylation or hypermethylation accordingly. To conclude, a foundation has been provided for screening CpG island methylation profiles as HCC biological markers.

View Figures

View References

1	Scarano MI, Strazzullo M, Matarazzo MR and D’Esposito M: DNA methylation 40 years later: Its role in human health and disease. J Cell Physiol. 204:21–35. 2005.PubMed/NCBI
2	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
3	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar
4	Pfister S, Schlaeger C, Mendrzyk F, et al: Array-based profiling of reference-independent methylation status (aprimes) identifies frequent promoter methylation and consecutive downregulation of zic2 in pediatric medulloblastoma. Nucleic Acids Res. 35:e512007. View Article : Google Scholar
5	Huang TH, Perry MR and Laux DE: Methylation profiling of cpg islands in human breast cancer cells. Hum Mol Genet. 8:459–470. 1999. View Article : Google Scholar : PubMed/NCBI
6	Yan PS, Potter D, Deatherage DE, Huang TH and Lin S: Differential methylation hybridization: profiling DNA methylation with a high-density cpg island microarray. Methods Mol Biol. 507:89–106. 2009. View Article : Google Scholar : PubMed/NCBI
7	Herath NI, Leggett BA and MacDonald GA: Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol. 21:15–21. 2006. View Article : Google Scholar : PubMed/NCBI
8	Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH and Surzycki SJ: Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology. 132:1476–1494. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wang L, Wang WL, Zhang Y, Guo SP, Zhang J and Li QL: Epigenetic and genetic alterations of pten in hepatocellular carcinoma. Hepatol Res. 37:389–396. 2007. View Article : Google Scholar : PubMed/NCBI
10	Calvisi DF, Ladu S, Gorden A, et al: Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 117:2713–2722. 2007. View Article : Google Scholar : PubMed/NCBI
11	Calvisi DF, Ladu S, Gorden A, et al: Molecular pathogenesis of human hepatocellular carcinoma: Mechanistic and prognostic significance of aberrant methylation. AACR Meeting Abstracts. 2006:763a2006.
12	Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
13	Pei Y, Zhang T, Renault V and Zhang X: An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochim Biophys Sin. 41:1–15. 2009. View Article : Google Scholar : PubMed/NCBI
14	Frommer M, McDonald LE, Millar DS, et al: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA. 89:1827–1831. 1992. View Article : Google Scholar : PubMed/NCBI
15	Humeniuk R, Mishra PJ, Bertino JR and Banerjee D: Molecular targets for epigenetic therapy of cancer. Curr Pharm Biotechnol. 10:161–165. 2009. View Article : Google Scholar : PubMed/NCBI
16	Schneider-Stock R and Ocker M: Epigenetic therapy in cancer: Molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs. 10:557–561. 2007.
17	Issa JP: Cpg island methylator phenotype in cancer. Nat Rev Cancer. 4:988–993. 2004. View Article : Google Scholar : PubMed/NCBI
18	Shen L, Catalano PJ, Benson AB III, O’Dwyer P, Hamilton SR and Issa JP: Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Cancer Res. 13:6093–6098. 2007. View Article : Google Scholar : PubMed/NCBI
19	Tommasi S, Pinto R, Pilato B and Paradiso A: Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des. 13:3279–3287. 2007. View Article : Google Scholar : PubMed/NCBI
20	Pang RW and Poon RT: From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 72(Suppl 1): 30–44. 2007. View Article : Google Scholar : PubMed/NCBI
21	Gollob JA, Wilhelm S, Carter C and Kelley SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/mek/erk signal transduction pathway. Semin Oncol. 33:392–406. 2006. View Article : Google Scholar : PubMed/NCBI
22	Prasad CP, Mirza S, Sharma G, et al: Epigenetic alterations of cdh1 and apc genes: relationship with activation of wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci. 83:318–325. 2008. View Article : Google Scholar : PubMed/NCBI
23	Banno K, Yanokura M, Susumu N, et al: Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep. 16:1189–1196. 2006.PubMed/NCBI
24	Supic G, Kozomara R, Brankovic-Magic M, Jovic N and Magic Z: Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol. 45:1051–1057. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kumar SR, Singh J, Xia G, et al: Receptor tyrosine kinase ephb4 is a survival factor in breast cancer. Am J Pathol. 169:279–293. 2006. View Article : Google Scholar : PubMed/NCBI
26	Noren NK, Lu M, Freeman AL, Koolpe M and Pasquale EB: Interplay between ephb4 on tumor cells and vascular ephrin-b2 regulates tumor growth. Proc Natl Acad Sci USA. 101:5583–5588. 2004. View Article : Google Scholar : PubMed/NCBI
27	Berclaz G, Karamitopoulou E, Mazzucchelli L, et al: Activation of the receptor protein tyrosine kinase ephb4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol. 14:220–226. 2003. View Article : Google Scholar : PubMed/NCBI
28	Bashaw GJ and Goodman CS: Chimeric axon guidance receptors: the cytoplasmic domains of slit and netrin receptors specify attraction versus repulsion. Cell. 97:917–926. 1999. View Article : Google Scholar : PubMed/NCBI
29	Stella MC, Trusolino L and Comoglio PM: The slit/robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. Mol Biol Cell. 20:642–657. 2009. View Article : Google Scholar : PubMed/NCBI
30	Liu ZJ and Herlyn M: Slit-Robo: neuronal guides signal in tumor angiogenesis. Cancer Cell. 4:1–2. 2003. View Article : Google Scholar : PubMed/NCBI
31	Marlow R, Strickland P, Lee JS, et al: Slits suppress tumor growth in vivo by silencing sdf1/cxcr4 within breast epithelium. Cancer Res. 68:7819–7827. 2008. View Article : Google Scholar : PubMed/NCBI
32	Wang B, Xiao Y, Ding BB, et al: Induction of tumor angiogenesis by slit-robo signaling and inhibition of cancer growth by blocking robo activity. Cancer Cell. 4:19–29. 2003. View Article : Google Scholar : PubMed/NCBI
33	Hohenester E: Structural insight into slit-robo signalling. Biochem Soc Trans. 36:251–256. 2008. View Article : Google Scholar : PubMed/NCBI